These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33241993)

  • 1. Inflammatory Activity and Treatment Response in Pediatric Compared to Adult Multiple Sclerosis: A Pilot, Retrospective and Observational Study of the First Year After Diagnosis.
    De Carvalho S; Pinto J; Correia I; Faustino R; Vasconcelos M; Sousa L; Palavra F
    Acta Med Port; 2021 Jan; 34(1):28-34. PubMed ID: 33241993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
    Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
    Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.
    Capobianco M; Bertolotto A; Malucchi S
    Neurol Sci; 2021 May; 42(Suppl 1):25-28. PubMed ID: 33712907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
    Zafar A; AlShamrani FJG
    Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
    Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
    He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
    Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
    Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
    Sinnecker T; Clarke MA; Meier D; Enzinger C; Calabrese M; De Stefano N; Pitiot A; Giorgio A; Schoonheim MM; Paul F; Pawlak MA; Schmidt R; Kappos L; Montalban X; Rovira À; Evangelou N; Wuerfel J;
    JAMA Neurol; 2019 Dec; 76(12):1446-1456. PubMed ID: 31424490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.
    Eden D; Gros C; Badji A; Dupont SM; De Leener B; Maranzano J; Zhuoquiong R; Liu Y; Granberg T; Ouellette R; Stawiarz L; Hillert J; Talbott J; Bannier E; Kerbrat A; Edan G; Labauge P; Callot V; Pelletier J; Audoin B; Rasoanandrianina H; Brisset JC; Valsasina P; Rocca MA; Filippi M; Bakshi R; Tauhid S; Prados F; Yiannakas M; Kearney H; Ciccarelli O; Smith SA; Andrada Treaba C; Mainero C; Lefeuvre J; Reich DS; Nair G; Shepherd TM; Charlson E; Tachibana Y; Hori M; Kamiya K; Chougar L; Narayanan S; Cohen-Adad J
    Brain; 2019 Mar; 142(3):633-646. PubMed ID: 30715195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7T MRI Visualization of Cortical Lesions in Adolescents and Young Adults with Pediatric-Onset Multiple Sclerosis.
    Datta R; Sethi V; Ly S; Waldman AT; Narula S; Dewey BE; Sati P; Reich D; Banwell B
    J Neuroimaging; 2017 Sep; 27(5):447-452. PubMed ID: 28796432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood-onset multiple sclerosis: report of 82 patients from Isfahan, Iran.
    Etemadifar M; Nasr-Esfahani AH; Khodabandehlou R; Maghzi AH
    Arch Iran Med; 2007 Apr; 10(2):152-6. PubMed ID: 17367215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis.
    Wybrecht D; Reuter F; Zaaraoui W; Faivre A; Crespy L; Rico A; Malikova I; Confort-Gouny S; Soulier E; Cozzone PJ; Pelletier J; Ranjeva JP; Audoin B
    Mult Scler; 2012 Nov; 18(11):1585-91. PubMed ID: 22454097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.